{ "@graph": [    { "@id": "http://linked.opendata.cz/resource/ATC/N05AH01",      "@type" : [ "http://linked.opendata.cz/ontology/drug-encyclopedia/ATCConcept" ] ,      "http://www.w3.org/2004/02/skos/core#prefLabel" : [ { "@value" : "Loxapine" , "@language" : "en" } ,        { "@value" : "Loxapin" , "@language" : "cs" } ] ,      "http://www.w3.org/2004/02/skos/core#notation" : [ { "@value" : "N05AH01" } ] } ,    { "@id": "http://linked.opendata.cz/resource/ndfrt/disease/N0000000999",      "@type" : [ "http://linked.opendata.cz/ontology/drug-encyclopedia/DiseaseOrFinding" ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/title" : [ { "@value" : "Drug hypersensitivity" , "@language" : "en" } ,        { "@value" : "L\u00E9kov\u00E1 alergie" , "@language" : "cs" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/description" : [ { "@value" : "Immunologically mediated adverse reactions to medicinal substances used legally or illegally.     " , "@language" : "en" } ] } ,    { "@id": "http://linked.opendata.cz/resource/ndfrt/disease/N0000000819",      "@type" : [ "http://linked.opendata.cz/ontology/drug-encyclopedia/DiseaseOrFinding" ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/title" : [ { "@value" : "Coma" , "@language" : "en" } ,        { "@value" : "K\u00F3ma" , "@language" : "cs" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/description" : [ { "@value" : "A profound state of unconsciousness associated with depressed cerebral activity from which the individual cannot be aroused. Coma generally occurs when there is dysfunction or injury involving both cerebral hemispheres or the brain stem RETICULAR FORMATION.     " , "@language" : "en" } ] } ,    { "@id": "http://linked.opendata.cz/resource/ndfrt/disease/N0000002532",      "@type" : [ "http://linked.opendata.cz/ontology/drug-encyclopedia/DiseaseOrFinding" ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/title" : [ { "@value" : "Psychotic disorders" , "@language" : "en" } ,        { "@value" : "Psychotick\u00E9 poruchy" , "@language" : "cs" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/description" : [ { "@value" : "Disorders in which there is a loss of ego boundaries or a gross impairment in reality testing with delusions or prominent hallucinations. (From DSM-IV, 1994)     " , "@language" : "en" } ] } ,    { "@id": "http://linked.opendata.cz/resource/ndfrt/physiologic-effect/N0000008893",      "@type" : [ "http://linked.opendata.cz/ontology/drug-encyclopedia/PhysiologicEffect" ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/title" : [ { "@value" : "Decreased Serotonin Activity" , "@language" : "en" } ] } ,    { "@id": "http://linked.opendata.cz/resource/ndfrt/physiologic-effect/N0000009282",      "@type" : [ "http://linked.opendata.cz/ontology/drug-encyclopedia/PhysiologicEffect" ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/title" : [ { "@value" : "Increased Dopamine Activity" , "@language" : "en" } ] } ,    { "@id": "http://linked.opendata.cz/resource/ndfrt/mechanism-of-action/N0000000130",      "@type" : [ "http://linked.opendata.cz/ontology/drug-encyclopedia/MechanismOfAction" ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/title" : [ { "@value" : "Serotonin Antagonists" , "@language" : "en" } ] } ,    { "@id": "http://linked.opendata.cz/resource/ndfrt/mechanism-of-action/N0000000230",      "@type" : [ "http://linked.opendata.cz/ontology/drug-encyclopedia/MechanismOfAction" ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/title" : [ { "@value" : "Dopamine Antagonists" , "@language" : "en" } ] } ,    { "@id": "http://linked.opendata.cz/resource/drug-encyclopedia/ingredient/M0012711",      "@type" : [ "http://linked.opendata.cz/ontology/drug-encyclopedia/Ingredient" ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/title" : [ { "@value" : "Loxapin" , "@language" : "cs" } ,        { "@value" : "Loxapine" , "@language" : "en" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasPharmacologicalAction" : [ "http://linked.opendata.cz/resource/drug-encyclopedia/pharmacological-action/M0021770" ,        "http://linked.opendata.cz/resource/drug-encyclopedia/pharmacological-action/M0027734" ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasMedicinalProduct" : [ "http://linked.opendata.cz/resource/sukl/medicinal-product/ADASUVE-4-5-MG" ,        "http://linked.opendata.cz/resource/sukl/medicinal-product/ADASUVE-9-1-MG" ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/description" : [ { "@value" : "An antipsychotic agent used in schizophrenia.     " , "@language" : "en" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasMechanismOfAction" : [ "http://linked.opendata.cz/resource/ndfrt/mechanism-of-action/N0000000130" ,        "http://linked.opendata.cz/resource/ndfrt/mechanism-of-action/N0000000230" ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasPregnancyCategory" : [ "http://linked.opendata.cz/resource/fda-spl/pregnancy-category/C" ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/mayTreat" : [ "http://linked.opendata.cz/resource/ndfrt/disease/N0000002532" ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/contraindicatedWith" : [ "http://linked.opendata.cz/resource/ndfrt/disease/N0000000999" ,        "http://linked.opendata.cz/resource/ndfrt/disease/N0000000819" ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasPhysiologicEffect" : [ "http://linked.opendata.cz/resource/ndfrt/physiologic-effect/N0000008893" ,        "http://linked.opendata.cz/resource/ndfrt/physiologic-effect/N0000009282" ] } ,    { "@id": "http://linked.opendata.cz/resource/sukl/medicinal-product/ADASUVE-4-5-MG",      "@type" : [ "http://linked.opendata.cz/ontology/drug-encyclopedia/MedicinalProduct" ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/title" : [ { "@value" : "ADASUVE 4,5 MG" , "@language" : "cs" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasATCConcept" : [ "http://linked.opendata.cz/resource/ATC/N05AH01" ] } ,    { "@id": "http://linked.opendata.cz/resource/sukl/medicinal-product/ADASUVE-9-1-MG",      "@type" : [ "http://linked.opendata.cz/ontology/drug-encyclopedia/MedicinalProduct" ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/title" : [ { "@value" : "ADASUVE 9,1 MG" , "@language" : "cs" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasATCConcept" : [ "http://linked.opendata.cz/resource/ATC/N05AH01" ] } ,    { "@id": "http://linked.opendata.cz/resource/drug-encyclopedia/pharmacological-action/M0021770",      "@type" : [ "http://linked.opendata.cz/ontology/drug-encyclopedia/PharmacologicalAction" ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/title" : [ { "@value" : "Antipsychotic agents" , "@language" : "en" } ,        { "@value" : "Antipsychotika" , "@language" : "cs" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/description" : [ { "@value" : "Agents that control agitated psychotic behavior, alleviate acute psychotic states, reduce psychotic symptoms, and exert a quieting effect. They are used in SCHIZOPHRENIA; senile dementia; transient psychosis following surgery; or MYOCARDIAL INFARCTION; etc. These drugs are often referred to as neuroleptics alluding to the tendency to produce neurological side effects, but not all antipsychotics are likely to produce such effects. Many of these drugs may also be effective against nausea, emesis, and pruritus.     " , "@language" : "en" } ] } ,    { "@id": "http://linked.opendata.cz/resource/drug-encyclopedia/pharmacological-action/M0027734",      "@type" : [ "http://linked.opendata.cz/ontology/drug-encyclopedia/PharmacologicalAction" ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/title" : [ { "@value" : "Dopamin - antagonist\u00E9" , "@language" : "cs" } ,        { "@value" : "Dopamine antagonists" , "@language" : "en" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/description" : [ { "@value" : "Drugs that bind to but do not activate DOPAMINE RECEPTORS, thereby blocking the actions of dopamine or exogenous agonists. Many drugs used in the treatment of psychotic disorders (ANTIPSYCHOTIC AGENTS) are dopamine antagonists, although their therapeutic effects may be due to long-term adjustments of the brain rather than to the acute effects of blocking dopamine receptors. Dopamine antagonists have been used for several other clinical purposes including as ANTIEMETICS, in the treatment of Tourette syndrome, and for hiccup. Dopamine receptor blockade is associated with NEUROLEPTIC MALIGNANT SYNDROME.     " , "@language" : "en" } ] }] }